Research output per year
Research output per year
Personal profile
Research interests
Astrid Murumägi is a senior scientist at the Kallioniemi research group. Her work is focused on applying functional precision medicine strategy in cancer research. In this approach cancer patients live tumor cells are cultured ex vivo and used for comprehensive drug sensitivity testing and molecular profiling to identify best treatment strategies for patients. She is involved in melanoma, ovarian and prostate cancer functional precision oncology projects.
Fields of Science
- 3111 Biomedicine
- 318 Medical biotechnology
- 3122 Cancers
International and National Collaboration
Publications and projects within past five years.
-
Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT)
Feoforoff, M., Mikkonen, P., Turunen, L., Hassinen, A., Paasonen, L., Paavolainen, L., Potdar, S., Murumagi, A., Kallioniemi, O. & Pietiainen, V., Jun 2023, In: SLAS discovery . 28, 4, p. 138-148 11 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
Murumägi, A., Ungureanu, D., Khan, S., Arjama, M., Välimäki, K., Ianevski, A., Ianevski, P., Bergstrom, R., Dini, A., Kanerva, A., Koivisto-Korander, R., Tapper, J., Lassus, H., Loukovaara, M., Mägi, A., Hirasawa, A., Aoki, D., Pietiäinen, V., Pellinen, T., Butzow, R., & 2 others, 16 Feb 2023, In: British Journal of Cancer. 128, 4, p. 678–690 13 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
Ollila-Raj, H., Murumägi, A., Pellinen, T., Arjama, M., Sutinen, E., Volmonen, K., Haikala, H. M., Kallioniemi, O., Mäyränpää, M. I. & Ilonen, I., Apr 2023, In: Lung Cancer. 178, p. 213-219 7 p.Research output: Contribution to journal › Article › Scientific › peer-review
-
Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates
Feodoroff, M. J., Mikkonen, P., Arjama, M., Murumägi, A., Kallioniemi, O., Potdar, S., Turunen, L. & Pietiäinen, V., Mar 2023, In: SLAS discovery . 28, 2, p. 36-41 6 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity
Piki, E., Dini, A., Raivola, J., Salokas, K., Zhang, K., Varjosalo, M., Pellinen, T., Välimäki, K., Veskimäe, K. T., Staff, S., Hautaniemi, S., Murumägi, A. & Ungureanu, D., 3 Jul 2023, In: Cell death discovery . 9, 1, 10 p., 222.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile
Activities
-
Future perspectives in ovarian cancer research
Astrid Murumägi (Attendee)
16 Nov 2022 → 17 Nov 2022Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
iCAN-FCI Symposium
Astrid Murumägi (Attendee)
22 Sep 2022 → 23 Sep 2022Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
Single Cell Symposium
Astrid Murumägi (Attendee)
5 Oct 2022Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
Functional Precision Medicine for Blood Cancer
Astrid Murumägi (Attendee)
5 Sep 2022 → 7 Sep 2022Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
Establishment of representative ex vivo patient-derived ovarian cancer models for personalized therapy
Astrid Murumägi (Co-supervisor) & Daniela Elena Ungureanu (Co-supervisor)
26 Jan 2022Activity: Examination types › Supervision of other thesis (Master's, Licentiate)